The companies on the Global 500 employ 70.2 million people, and their revenue represents more than one-third of the world’s GDP.

Fortune Global 500

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The corporations on our annual list of the world's 500 largest companies combined to generate $41.7 trillion in revenue over the past year.

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The corporations on our annual list posted aggregate revenues of $41 trillion for the second year in a row.

Industries included in the sector are beverages, food consumer products, and food production.

Fortune Sector Leaders: Food, Beverages, and Tobacco

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The corporations on our annual list of the world’s largest companies delivered a record $41 trillion in aggregate revenues.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Aggregate sales hit $37.8 trillion last year—an increase of 19%, the highest annual growth rate in the list’s history.

Fortune collaborated with the Diligent Institute to rank the most innovative boards of directors among S&P 500.

Modern Board 2022-Philip Morris

Philip Morris International scored high on board independence, age dispersion, and nationality dispersion.  
 
Not to be confused with Philip Morris USA, a division of tobacco corporation Altria Group, PMI is the distributor of cigarette brands including Marlboro in international markets. Now heavily investing in smokeless nicotine devices, the company has taken to <a href="https://fortune.com/2021/07/26/cigarette-ban-uk-philip-morris-ceo-jacek-olczak/">advocating for a ban on cigarettes</a> within the next decade. “In 10 to 15 years, we think cigarettes can be out of the market entirely,” PMI America CEO Martin King told <a href="https://www.latimes.com/business/story/2021-04-16/q-a-with-the-ceo-of-philip-morris-international-america">the Los Angeles Times</a> in 2021. IQOS, PMI’s smoke-free tobacco product, is now available in over 60 markets. 
 
The company has a good track record in taking care of shareholders. Despite a setback from PMI’s recent decision to pull out of Russia, which accounted for 6% of PMI’s 2021 net revenue, <a href="https://seekingalpha.com/article/4497780-philip-morris-cutting-forecasts-reiterate-buy">analysts forecast</a> a total return of 49% through 2025. Analysts have <a href="https://seekingalpha.com/article/4495379-philip-morris-20-percent-off-recent-highs-but-still-not-a-bargain">also noted</a> that PMI’s dividend growth and $7 billion stock buyback plan, approved last June and resulting in 8.5 million repurchased stocks in the latter half of 2021, will enable significant return of capital to investors. 
 
Former PMI CEO André Calantzopoulos is the chair of the board. The roster of directors includes nine former or current CEOs including PMI’s own chief, Jacek Olczak; SoftBank Group International CEO Michel Combes; and Lucio Noto, chairman and CEO of Mobil prior to its 1999 merger with Exxon. Former Goldman Sachs general partner and managing director Jun Makihara is also on the board, along with Advent International partner and Goodyear Tire &amp; Rubber Co. board member Werner Geissler, and Dessi Temperley, former head of investor relations at Nestlé and current board member with Coca-Cola Europacific Partners, Corbion, and Cimpress.

Fortune Modern Board 25

This year’s Fortune 500 marks the 68th running of the list.

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

After nearly two centuries of selling cigarettes, the holding company is investing heavily into smokeless nicotine devices. The company's tobacco heating system, IQOS, is now sold is more than 60 countries. “In 10 to 15 years, we think cigarettes can be out of the market entirely," CEO Martin King told the Los Angeles Times.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-101-Philip Morris International

This year's Fortune Global 500 generated $33.3 trillion in revenues and $2.1 trillion in profits.

G500-2020-421-Philip-Morris-International

This global conglomerate sells cigarettes and other tobacco products outside of the U.S.; more recently, it has begun focusing on smoke-free alternatives like "heat not burn" devices, which in July received FDA approval to be marketed as a safer alternative to cigarettes.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-107-Philip-Morris

This global conglomerate sells cigarettes and other tobacco products outside of the U.S.; more recently, it has begun focusing on smoke-free alternatives like "heat not burn" devices.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Global business is back. After limping through a worldwide financial crisis and economic slowdown, the 500 largest companies ranked by revenues shattered all sorts of performance records in 2013: They racked up combined revenues of $31.1 trillion, up 2.5% from 2012, and profits soared 27% to nearly $2 trillion. China’s 95 companies (up from 89 last year) posted $5.8 trillion in revenues. The U.S. has four fewer companies on the list than last year but remains (for now) the country leader, with 128 corporations on the list—including No. 1 Wal-Mart Stores—reporting $8.6 trillion in revenues. 

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Founded in 1847 as a London tobacco shop, Philip Morris International is now one of the world’s largest tobacco companies and the conglomerate behind Marlboro and Parliament cigarettes, as well as Zyn nicotine pouches. In 2016, PMI set a goal for a “smoke-free future” for the company, planning to eventually eliminate the sale of its combustible tobacco products. Since then, PMI has pushed the expansion of noncombustible nicotine products like heat-not-burn tobacco products and e-cigarettes. It acquired Swedish Match, the creator of Zyn, in 2022.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Philip Morris International (PM): Company Profile, Stock Price, News, Rankings

legacy

Philip Morris International

philip morris international

Good day, and thank you for standing by. Welcome to the Philip Morris International twenty twenty five Second Quarter Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.

You will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, James Bushnell, Vice President, Investor Relations. Please go ahead.

Welcome, and good morning. Thank you for joining us. Earlier today, we issued a press release containing detailed information on our twenty twenty five second quarter results. The press release is available on our website at pmi.com. A glossary of terms including the definition for smoke free products as well as adjustments, other calculations and reconciliations to the most directly comparable U.

S. GAAP measures for non GAAP financial measures cited in this presentation are available in Exhibit 99.2 to the company's Form eight ks dated today and on our Investor Relations website. Today's remarks contain forward looking statements and projections of future results. I direct your attention to the forward looking and cautionary statements disclosure in today's presentation and press release for a review of the various factors that could cause actual results to differ materially from projections or forward looking statements. I'm joined today by Emmanuel Babeau, Chief Financial Officer. Over to you, Emmanuel.

Thank you, James, and welcome, everyone. We delivered an excellent set of H1 results following another very strong performance in the second quarter of twenty twenty five. Top line dynamism from our smoke free portfolio, which reached a record $4,000,000,000 in net revenues, coupled with margin improvements across our business, drove strong double digit adjusted diluted earnings per share growth in both constant currency and dollar terms. The multi category momentum of our smoke free business accelerated with the Q2 step up in offtake growth for IQOS, ZYN and VEV. As expected, IQOS delivered another strong performance with heated tobacco unit adjusted in market sales growth accelerating to plus 11.4% in Q2.

This reflects broad based growth, both globally and in Europe, as markets such as Italy pass the transitory disruption of the characterizing flavor ban. ZYN confirmed its upward trajectory with a significant acceleration in U. S. Consumer Offset growth to plus 26% for Q2 and plus 36% in June as in store availability improved. Internationally, Q2 nicotine pouch volumes increased plus 65 and almost tripled outside The Nordics.

In e vapor, Vive continued its remarkable trajectory with shipments more than doubling year on year, driving further gross margin expansion. For Combustibles, despite an expected return to modest volume declines, our business delivered robust top and bottom line performance, reflecting its resilient model led by strong pricing. We continue to generate best in class growth across the P and L with high single digit organic H1 top line growth and mid teens adjusted OI growth to reach a margin of over 41%. This high quality performance reflects the increasing profitability of our three smoke free categories at scale, operating leverage and efficiencies combined. These results provide an excellent platform for another year of superior growth.

We expect strong smoke free momentum to continue in H2, while we factor in the exceptional H2 prior year comparison notably on growing combustible volumes and certain timing factors. With strong business fundamentals and a slightly more favorable expected tax rate, we are raising our adjusted diluted EPS full year forecast to plus 13% to plus 15% growth or plus 11.5% to plus 13.5%, excluding currency. Looking at our Q2 financials, we delivered another quarter of shipment volume growth of plus 1.2% and organic top line growth of plus 6.8% or plus 7.1% in dollar terms to reach over $10,000,000,000 in quarterly net revenues for the first time. Excluding the Indonesia technical impact explained last quarter, organic net revenues grew by more than plus 8%. Adjusted OI grew by plus 14.9% organically, with growing profitability in all categories, positive smoke free margin mix and ongoing cost efficiencies.

Adjusted diluted EPS of $1.91 reflects growth of plus 20%, including a favorable currency variance of $02 $0.04 lower than previously guided, mainly due to intercompany transactional impact from currency volatility at period end, including on the Swiss franc. This better than expected EPS delivery notably reflects strong top line momentum, positive margin evolution in our smoke free product business and robust combustible pricing. Combining this excellent Q2 with a strong quarter, we achieved one of our strongest ever H1 performances. Total shipment volumes grew by plus 2.5% and organic net revenues by plus 8.4% or approximately plus 10% excluding the Indonesia technical impact. Strong performance from both smoke free and combustibles drove adjusted operating income growth of circa plus 15% in both organic and USD terms to reach $8,000,000,000 in total.

H1 adjusted diluted EPS was up by plus 17.7% in constant currency and by plus 16.1% in dollar terms. Turning to shipment volumes. We delivered Q2 growth of plus 1.2% and plus 2.5% for the first half, driven by more than plus 13% growth from our Smokefree business. While adjusted in market sales growth accelerated, Q2 HTU shipment volume grew plus 9.2% to 38,800,000,000 units, including robust growth in Europe and Japan as well as promising growth from global markets such as Indonesia, South Korea and global travel retail. H1 HTU shipments increased by plus 10.5%, broadly in line with adjusted in market sales growth.

As mentioned last quarter, our H1 shipments include a Q1 shipment timing benefit of around 1,000,000,000 units, which we expect to reverse in the fourth quarter. Oral and e vapor shipments again grew significantly. Cigarette volumes declined modestly in Q2 following the exceptional growth of recent quarters. This was primarily due to contraction in Indonesia and in Turkey, where we experienced supply chain issues following a change in regulatory requirements. This resulted in a temporary loss of volume and share with some associated inventory write downs.

We expect a gradual recovery through the remainder of the year, though H2 year on year comparisons are still likely to be affected. In Indonesia, despite a good share performance, a growing illicit segment is impacting both the legal industry and our volumes within it, and this is also likely to extend into H2. We expect our cigarette volumes to decline around 2% for the year, more in line with the historic underlying trend. This includes a forecast decline of 3% to 4% in H2 against the high prior year comparison I mentioned, with Turkey accounting for close to half of this decline. This also factors the continuation of decline in Europe and Japan as smoke free product grows strongly and the dynamic in Indonesia and in Egypt, where the recovery of the main local competitor is ongoing after previous supply constraints.

As a testament to the resilience of our combustible model, we are still targeting combustible gross profit growth in H2, supported by pricing and cost efficiencies. For smoke free products, we anticipate continued double digit volume growth in H2, including the expected reversal of H1 phasing benefit on IQOS. However, given cigarette dynamics, it is possible that H2 may see modest decline for total PMI volumes. Importantly, with a forecast full year increase of around plus 1%, we continue to target our fifth consecutive year of total volume growth, as we do for future years as our Smokefree portfolio continues to drive performance. Breaking the performance down by category, exceptional gross margin and OI growth in Q2 resulted in impressive first half results powered by our increasingly profitable Smokefree business.

H1 Smokefree net revenue grew organically by plus 17.3% to $8,100,000,000 and gross profit by plus 27% to $5,600,000,000 with plus five thirty basis points of organic expansion to reach over 70% gross margin. This is around 4.5 points above the gross margin of combustible at the current category and geographic mix. As in 2024, this reflects continued margin expansion for all three smoke free category, notably combined with the positive mix impact of ZYN's accretive unit economics and pricing on both HTUs and ZYN. Very strong IQOS gross margin expansion reflects the powerful growth and scale effect of this large and growing business, manufacturing productivities and a comparison benefit from higher device shipment in the prior year when Illumina I was launched in Japan and other markets. We expect strong margin to continue in H2, albeit without the device year on year comparison benefit as we also further expand the presence of IlluminaEye across market and bonds in Indonesia.

Combustible net revenues increased by plus 2.9% or more than 5% excluding the Indonesia technical impact. Gross profit grew by plus 5%, driving plus 140 basis points of margin expansion despite the financial impact of the Turkey disruption. This includes a robust Q2 with organic net revenue growth of plus 2% and gross profit growth of plus 4.8%. This performance epitomizes the resilience of our ongoing combustible business model with low single digit volume declines, robust pricing and efficiencies combining to deliver top line and gross profit growth over time. We continue to target combustible gross margin expansion organically and in dollar terms for the year despite slower pricing and weaker volume in H2.

The combination of sustained smoke free momentum and combustible resilience led to plus 15.4% H1 organic OI growth at total PMI level, resulting in plus two fifty basis points of operating income margin expansion to surpass 41%. H1 net revenue growth of plus 8.4% was again fueled by the three engines of our top line growth model, with positive volumes, robust pricing and favorable smoke free mix. Pricing contributed plus 5.2 points, driven by combustible pricing of plus 7.7% and low single digit smoke free pricing excluding devices. The positive mix impact of rapid SFP growth drove a further contribution of plus 3.1 points. Combustible geographic mix and other factors had an unfavorable impact of 2.4 points, including the Indonesia technical impact of around 1.5 points.

Currency had a negative impact of 1.5 points, with a further 0.4 points from acquisition and divestitures, which include the divestments of Vectura. Turning now to gross margins. We delivered H1 organic expansion of plus 300 basis points and plus three twenty basis points, including currency, acquisition and divestitures. Pricing made a plus 160 basis point contribution, more than offsetting the 60 basis point unfavorable impact from cost inflation, net of productivity and other cost items. Smokefree growth drove an excellent plus 190 basis points, reflecting the factors I covered earlier.

The impact of combustible was broadly flat excluding pricing, but including the Indonesia impact. Below gross profit, we continue to invest strongly in the future growth of our smoke free brands, including in The U. S, with SG and A organic growth of plus 10.6% for H1, marginally above net revenue growth, excluding the technical impact of Indonesia. We achieved more than $500,000,000 in gross cost saving year to date through our manufacturing and back office efficiency initiatives. Now at the midpoint of our target twenty four-twenty twenty six period, we have delivered over $1,200,000,000 placing us well on track towards our $2,000,000,000 objective.

Altogether, with gross margin expansion more than compensating for higher year on year commercial investments, we delivered plus two ninety basis points of adjusted operating income margin expansion in H1 or plus two fifty basis points organically. Q2 organic OI margin expansion of plus 300 basis points was even stronger than the plus 200 basis points in our first quarter. Focusing now on our smoke free business, where our multi category strategy is facilitating the continuous growth of our smoke free user base. Estimated legal age consumer of our SSPs grew by approximately 5,000,000 versus one year ago, reaching around 41,500,000 as of June 30. Our smoke free products are now available in 97 markets following the Q2 launch of ZYN in Ireland and Cambodia.

Almost half of these markets now have a multi category offer with at least two of ICO's ZYN and VIVE on sale to legal age nicotine users. As shown on this slide, we now have all three categories deployed in 20 markets as we continue to broaden our multi category presence. The regulatory environment is a key enabler of smoke free growth and I'm pleased to report some more examples of positive progress, such as legislation providing new market access for one or more SFP category across several Middle East markets. We also note the recently published proposal to revise the EU Tobacco Excise Directive, which marks the start of a formal legislative process that will require unanimous approval by all Member States and subsequent transposition into national law. Many Member States have already adopted risk proportionate regulation and taxation frameworks for smoke free products, which can serve as a valuable foundation and benchmark for shaping the final directive.

While we know the clear differentiation for smoke free product relative to combustible in the proposed minimum rates, we are also disappointed to observe the lack of a plan to counter the threat of illicit trade, which accounted for 9.2% of total EU cigarette consumption in 2024, with governments losing over EUR14 billion in tax revenue at a time when many countries face intense economic pressure. Our multi category approach is built on the strength of the brand and commercial presence of IQOS, which remains our core smoke free product growth engine. We continue to be laser focused on maximizing the growth of IQOS over time, with the deployment of ZYN and VIVE under its umbrella, offering complementary opportunities to fully transition legal edge nicotine users from cigarettes to SSPs. In this context, I'm especially pleased to confirm the acceleration in ICO's HTU adjusted in market sales growth to plus 11.4% in Q2, notably driven by Europe and including excellent progress in its largest market of Italy as the impact of the characterizing flavor ban recedes and our commercial initiatives bear fruit. Japan also delivered another robust quarter of growth and other global markets accelerated nicely.

While competitive activity is increasing, we see this as positive for category growth over time and we expect continued strong IQOS progress in H2. We continue to target plus 10% to plus 12% HTU adjusted IMS growth for the year. Continuous IQOS innovation on devices and consumables, combined with investments in brand equity, are fundamental pillars of our growth. The rollout of the Illumi Eye technology, now present in over 30 markets, remains ongoing. We are expanding the portfolio of Livia tobacco free consumables with promising initial results from recently launched new test variants and flavor capsules.

We also commenced the rollout of a RIVEN PACK design on our core premium Terria HTUs, as well as the expansion of our mainstream price offering Delia, with excellent results in markets such as Germany and Poland. In The US, we continue with small scale IQOS three pilots, which are generating considerable adult consumer interest. As we progress our commercial pilot in Austin, we also launched a second pilot in Fort Lauderdale during the quarter with further initiatives planned in the coming months as we prepare for the at scale launch of IQOS ILUMA once authorized by the FDA. Our second flagship premium smoke free brand, ZYN, leads a category which has the potential to fundamentally reshape the consumption of nicotine for the substantial net benefit of global public health as adult smokers increasingly switch to smoke free product. Q2 can shipments grew by plus 43% on a global basis and off take reaccelerated strongly in The U.

S, which I'll come back to in more detail. Building on ZYN U. S. Strength, our global rollout continued to advance with Q2 international can volume up plus 65% year on year or a remarkable plus 179 excluding The Nordics. The growth of our international business reflects both market expansion and strong offtake growth, supported by expanding production capacity in new geographies.

Notable strong performances include our global Travel Retail business, with close to plus 200% volume excluding The U. S. As well as The UK, Pakistan, Poland, South Africa and Mexico. As covered in our recent Europe Focus event, our focus is on growing the category by switching legal age smokers rather than sourcing from the small existing category. It is also notable that ZYN holds the number one position in Mexico and South Africa, where we launched our predominantly mini dry portfolio at the same time as competitor brands.

Dry pouches already make up the majority of our pouch volumes in more than three quarters of ZYN market and we believe this format is especially relevant for legal age smokers. ZYN is now present in 44 markets globally, following additional launches in Q2. Our Smokefree trilogy is completed by Vive. H1 shipment volumes more than doubled to reach almost EUR 1,500,000,000.0 equivalent unit with increasingly profitable growth driven by Europe, where Vive now holds the number one close spot position in six markets, including Italy and Greece. Outside Europe, we see significant potential for the brand with nice results in diverse markets such as Indonesia, Canada and Colombia and further rollout plan.

Increasing repeat purchase rates and consumer loyalty are especially promising as we seek to leverage our multi category infrastructure under the IQOS umbrella of quality, premiumness and superior technology. In this vein, we recently launched our latest innovation VIVE in PRIME in The Czech Republic. In Prime offers an upgraded premium user experience with higher intensity of flavors, a larger cloud size and higher battery capacity with an optimized podcast profile. The most developed multi category consumer landscape is in Europe, and we now have 30 markets with at least two categories on offer. Of course, IQOS remains the core driver of our performance in the region, and I'm delighted to report a meaningful Q2 acceleration of HTU adjusted in market sales growth to plus 9.1%, as adjusted market share grew by plus 1.2 points year on year to 10.9% in this seasonally higher period for combustibles.

As explained at our recent Europe event, IQOS has a very strong brand platform across the region and this performance reflects our innovation and commercial initiatives, including those on Illumi, Livia and Delia. This helped drive strong double digit adjusted IMS growth across markets, including Germany, Spain, Romania, Greece and Bulgaria. A significant Q2 callout is Italy, Europe's largest IQOS market by volume, which delivered a very welcome uptick in both sequential and year on year growth. With the exception of Poland, Austria, Estonia and Croatia, the impact of the EU characterizing flavour ban is now behind us and our absolute regional growth in HTU adjusted AMS is now getting closer to pre band levels. While quarterly comparison from 2024 have some volatility from flavor band dynamics, sequential trends are very positive and we look forward to the remainder of the year with confidence in further strong IQOS growth.

On top of this IQOS progression, the accretion from our multi category strategy is evident in our total volume of IQOS ZYN and VEV with shipment growth of plus 13.5% in Q2 compared to HTUs alone at plus 10.5%. ZYN and VEV are still very early in their development but are demonstrating exceptional growth. The numbers you see here are for Europe overall and I would also note that where we are present with all three brands such as Italy, Greece, Poland and Romania, we see several points higher SFP volume growth. In Japan, we achieved a significant milestone of 10,000,000 estimated users and Q2 adjusted HTU shares increased plus 2.3 percentage points year on year to 31.7% despite increased competitive intensity. IQOS continues to deliver strong progress with Q2 adjusted IMS growth of plus 7.8% against the prior year period, which included the full launch of Illumina Eye.

As shown on the slide, iQOS delivered truly exceptional growth in 2023 and 2024, especially considering the size of the category now stands at almost half of total nicotine offtake volume nationally and more than half in certain cities. The high single digit growth that our business delivered in H1 twenty twenty five remains very healthy and is essentially in line with the trend in the years prior. We expect further strong adjusted IMS growth in the remainder of the year. We are pleased to see our competitors embrace the hypnot burn category as while our category share was sequentially stable at around 70% in Q2, Our biggest focus is on accelerating the size of smoke free product overall to maximize the growth of our leading proposition and convert more smokers. Switching now to The US.

The strong reacceleration in ZYN offtake growth is a clear highlight of our Q2 performance and testament to the strength of the brand as in store availability improves and legal edge consumers regain access to the full ZYN portfolio offering. The supply constraint of previous quarters had limited the growth in sell out volumes and meant ZYN was growing less than the overall category. With manufacturing capacity now in very good shape, the recovery to around plus 36% off tech volume growth in June, as measured by Nielsen and plus 26% in Q2 overall, marked the return of ZYN to its category driving position in terms of growth and market share. On a sequential basis, ZYN offtake volume accelerated to around plus 12% growth versus Q1, in line with the total category. With a number of commercial program restarting at the end of the quarter, this is clearly very promising as we increasingly focus on legal age smokers and vapers who have not yet switched to the category.

Q2 shipments increased plus 41% year on year, reaching 190,000,000 cans. As with any out of stock situation, quarterly shipments are subject to volatility. Restocking of the value chain was effectively completed in H1, with the majority of this taking place in the first quarter. We estimate the total net impact at broadly 14,000,000 cans for the year, slightly below our initial expectation. This factors in the good news that retail availability is now approaching normalized level, with a lower scarcity premium in retail prices narrowing the price gap to competition.

Importantly, sales velocities are accelerating and with 36% offtake growth in June, this bodes well for the second half of the year. With shipments now primarily driven by consumer offtake, we expect a broadly similar level of shipment in Q3 as in Q2, factoring in the possibility of a few days adjustment to wholesaler and distributor inventory as the situation fully normalize. We continue to target full year U. S. Shipment of 800,000,000 to eight forty million cans, including a sequential step up in Q4.

With our U. S. Production capacity increase ahead of plan and now well set for this year and beyond, we are incredibly excited to drive ZYN and the overall nicotine pouch category to its full potential over the coming years. Having covered Europe, Japan and The US in some detail, let's look at the rest of the world. In most markets, both the nicotine pouch category and our multi category presence are nascent.

Both ZYN and Vive will leverage on the strength of IQOS, where Q2 adjusted in market sales accelerated to plus 19.3% growth with broad based progress including Egypt, The Philippines and Indonesia. While pouch and e vapor volumes are naturally very small across this market at this stage, we can measure their Q2 growth in multiple rather than percentages. This impressive IQOS growth is exemplified by offtech share gains in global key cities. Strong presence in South Korea and Malaysia is more than matched by key cities in Mexico, Serbia, The Middle East and North Africa. Global Travel Retail, where multi category is increasingly prominent, also continues to grow strongly.

The world's largest cigarette market by volume outside China is Indonesia, where Jakarta Oftech share grew by plus 2.5 points year on year to 7.5%. Following promising results from the pilot launch of our full flavour hypnot burn technology, Bonds, which is tailored to local Cretek test preferences, we have recently commenced a broader rollout. Bond is also progressing well in Lebanon. Turning to combustible. Our business delivered robust organic net revenue growth of 2% in Q2 and plus 2.9% for H1, with Marlboro reaching a postpaid category share high of 10.7% in Q2.

Strong Q2 pricing of plus 7.2% included notable contribution from Indonesia, Germany and Italy, yielding plus 7.7% in H1 overall. While we continue to expect a moderation in H2 pricing due to timing and comparison dynamic, we now forecast plus 6% to plus 7% for the full year. Our strategy is to take pricing action to optimize the financial contribution to the business over time, which can naturally impact volume and share performance on a quarterly basis. Our combustible business is resilient and the combination of pricing, category leadership and ongoing efficiencies drove very good gross profit growth as covered earlier. This performance is in line with our objective of maximizing value over time and supporting the growth of our Smokefree business.

This brings me to our revised outlook for a remarkable 2025, where we are raising our adjusted diluted EPS forecast for the year in both currency neutral and dollar terms. As expected, we delivered a strong H1 organic performance compared to our target ranges for the full year. While combustible volume dynamic and the phasing of comparison and costs are less favorable in H2, our fundamental outlook remains very good. We expect continued strong momentum on both IQOS and ZYN alongside robust pricing and meaningful margin improvement. We expect further double digit HTU adjusted IMS progression with growth skewed to the fourth quarter given a strong comparison in Q3.

We forecast Q3 HTU shipment of EUR 38,500,000,000.0 to 39,500,000,000.0 and dynamic growth in adjusted diluted EPS to EUR 2.08 to EUR 2.13, including strong investment and a favorable currency variance of $05 at prevailing rates. For the full year, we continue to expect very strong organic net revenue growth in the range of plus 6% to plus 8%. Following excellent H1 top line dynamism and margin progression, we are raising our forecast range for organic operating income growth to plus 11% to plus 12.5%. We are also raising our currency neutral adjusted diluted EPS growth to plus 11.5% to plus 13.5%. This includes a slightly improved effective corporate tax rate of approximately 22% to 23% based on the latest assessment of tax dynamic and market mix.

We are still reviewing the implication of the OBBB Act U. S. Tax reform. In dollar terms, we expect adjusted diluted EPS growth of plus 13% to plus 15%. This includes an estimated €0.10 favorable currency impact at prevailing exchange rate, with favorable earnings translation from a broadly weaker dollar partly offset by transactional impact due to currency volatility, which I covered earlier.

Given our expectation for a strong full year profit delivery and cash conversion, we are raising our forecast for operating cash flow to around $11,500,000,000 at prevailing exchange rate and subject to year end working capital requirement. We project capital expenditures slightly above our prior forecast at around $1,600,000,000 primarily due to further international zinc capacity investment with CapEx spend almost entirely focused on supporting the growth of Smokefree. With regard to our balance sheet, we continue to target further deleveraging in 2025, placing us on track for our target ratio of around two times by the end of twenty twenty six. As mentioned last quarter, we are a global company with broadly diversified production and a worldwide supplier network, including an established U. S.

Manufacturing base, and we believe we are well positioned to mitigate potential supply chain challenges. While the situation is volatile, we do not currently anticipate a material impact on our business from recently introduced or discussed tariffs. Our financial growth model is driving a continuous improvement in the quality of our business, with smoke free accretion and combustible resilience driving considerable bottom line growth. We are well on track to meet or exceed our three year CAGR targets, demonstrating our ability to deliver what we believe to be best in class CPG growth. Adjusted diluted EPS growth in dollar term is a key objective and we are pleased to see this delivered in H1 as well as in our outlook for the year.

I will now conclude today's presentation with some closing remarks. We delivered an exceptional first half of the year, placing us well on track for another year of strong performance. Our smoke free growth is increasingly profitable as IQOS, ZYN and VIVE gain scale and drive synergies at the consumer and commercial level. Our best in class financial performance is bolstered by underlying strengths across all categories, including the resilience of our combustible business in addition to our proactive measures on pricing and cost efficiencies. This drives our confidence in strong and sustainable adjusted diluted EPS growth in both currency neutral and dollar terms.

Finally, we remain a highly cash generative business with an unwavering commitment to our progressive dividend policy. We look forward to further rewarding our shareholders as our transformation delivers continued growth. Thank you and we are now very happy to answer your questions.

Our first question comes from Gaurav Jain with Barclays. Your line is open.

Thank you for taking my question. So a few questions from me. One is on Zen. So you are saying that restock was less than what you had expected. So how should one read it that your expectations for future growth, they were higher earlier, and now they are lower.

And not only yours, but the market expectations were higher, and now they are lower. And that's why the need for restock is lower. And in that context, if I look at your ZYN volume guide, so if I say three q is flat versus two q, and in four q, you need to do 219 to two fifty nine million cans for that 800 to eight forty guide range, which would imply almost 15% to 36% growth on a Q o Q basis. And I remember from covering Swedish Match, you know, a few years ago that Q four actually used to have lesser shipping days for them. So they didn't really used to grow Q4 over Q3.

Can you just help me understand all the moving parts from them?

Sure, Grah. With great pleasure. So first of all, on the impact of the Well, let's be a bit humble here. We talk about a brand that we're targeting to deliver for the year 800,000,000 to eight forty million cans.

There are several weeks of inventory between wholesaler, distributor and the retailers. I'm not able to tell you a precise number. It's probably anywhere between, let's say, six to seven weeks altogether. And here we are talking, when we say it's a bit lower, I mean, it's clear that, for instance, at the retailer level, had no precise idea of the level of inventory. So we are a bit below our expectation.

If I was give a number, it's probably maybe 10,000,000, 20,000,000 cans below. Frankly, I'm not able to be more specific than that. We are talking about a few days of sales. So it's really small. So that's really what we're talking about.

And again, we've been facing this significant out of stock situation. We had the exercise of reloading, the good news that it's behind us. We made a few assumptions on what it would mean in terms of restocking. Okay, we've been probably a bit higher versus what was really needed, but this is it. So I don't think there is anything else to be read there.

And at the end of the day, I think we should focus on what is really important, which is the great dynamism that ZYN is facing now that there is full availability. Indeed, June was growing 36% in terms of consumer offtake according to Nielsen. If I look at the first two weeks of July, we are north of 37%. I think the market is a bit above 39%. So basically, we are growing now in line with the market.

So it just shows that we have absolutely resumed a strong momentum and that, of course, bodes very well for the future. As at the same time, as I mentioned, we are really restarting promotional advertising commercial activity in three sixty degree matters, I would say. So that's really what I think is important. On the sequence, so in my remarks, I noted the fact that there may be some adjustments as people have been maybe buying ZYN in a kind of mindset of shortages And we think there could be some adjustment on the volume here and there in Q3. So that can impact the Q3 performance.

And then we say there is a step up in Q4. At the end of the day, we are now in a dynamic where we are quarter on quarter growing nicely. I think the growth in the second quarter, 12% versus Q1, was by far the biggest sequential growth quarter on quarter since the first quarter of twenty twenty four. So we are absolutely back to renewed dynamism and we are growing fast year on year and that's what is driving our expectation for volume growth in the next months.

Sure. And my second question is just on EU TED, like you referenced a few comments, but could you help us understand in more detail, like what exactly are the proposals in terms of different tax rates on NGP products? And if there is any update on EUTPD as well?

Gaurav, I'm not going to elaborate on the initial proposal. We are at the beginning of a long process. Last time it was 2010, 2011, it took two years I think from the beginning to the end. A lot of discussion will happen. I reminded everybody that it requires unanimity from the parties.

So I'm not going to comment on things until there is more clarity on what's going to happen. The process has started. There will be several steps. As I said last time, took almost two years. And of course, when we have more clarity on what is really likely to happen, then of course at that moment we'll comment the implication.

In my remarks, I noted the two points which are important for us for the time being. One is the fact that the initial proposal is indeed coming with differentiation between smoke free and combustible when it comes to minimum taxation. So that's an important element. And the second that as an element which we hope will be improved, obviously, there is nothing when it comes to illicit, which is I think a real question for the European Union to tackle. That's what we can say for the time being.

Thank you. Our next question comes from Eric Serrato with Morgan Stanley. Your line is open.

morning. A couple of questions. First, in terms of IQOS, ILUMA U. S. Approval timing, I think you said you mentioned launch once authorized by the FDA.

Are you guys still sticking to your expectation of a second half authorization, realizing it's not something you have control over? And then second, when you look at international ICOs, can you talk a bit about some of the drivers of the reacceleration in IMS and sort of the sustainability for the second half of the year? Thank you.

Sure, Eric. So first on The U. S. So I mean, we don't have anything new to report on the potential PMTA for ICOS ILUMA. I think everybody can see that FDA is resuming activity on PMTA and that's good news.

As far as we are concerned, and this is public information, there is now for the renewal of the MRTP on ICO3, there is a Tobacco Product Scientific Advisory Committee that has been scheduled. They have also opened a docket for ZYN MRTP. So a number of things are happening. And that's what we know for the time being. So I have nothing new to report on the PMTA for icosiluma.

We are still hoping for an approval in H2, but we are also at the same time acknowledging the fact that the agenda and the workload for the FDA is very heavy. And therefore, it is clear that we don't have a certainty that we will give we will get this PMTA in 2025. And that could move, of course, to 2026. On the second question on the reason for the acceleration of IQOS, I mentioned, I think many of them. I think it's really Europe where you have now the effect of the characterizing flavor ban that are waning and a number of markets reaccelerating.

Some markets doing really very strong performance. I mentioned some of them like Spain, Germany, Romania, Bulgaria. It's great to see Italy reaccelerating as well. So I would say momentum is rebuilding. Now there will be some phasing last year on the performance in Europe, but I think we are expecting a nice performance overall for H2.

And outside Europe, we expect continued very nice performance from Japan and have been elaborating on the trend there where we continue to do very well. And there are all these new growth markets that are super exciting. And of course, global travel retail is one of them. But Indonesia, many countries in the Gulf Region, Mexico, Philippines. Are plenty of markets where we see very nice growth trajectory and growth potential for IQOS.

And in this new growth market, the momentum I would say is progressively building up.

Great. And just one follow-up on combustibles. Your volume is down 1.5%, or I should say only 1.5% despite the headwinds you called out in Turkey and Indonesia. Was that actually a little bit better than you expected since you guys have been pretty upfront really since last year that you expect combustibles volumes to resume their declines in 2025?

So you're right. Globally today, when we say that for the year we are targeting to be around minus 2% in terms of shipment, that's something that I had the opportunity to say in previous instances very clearly. The fact that we believe we are going to be back to what we think is a long term trend for the combustible business, which is a low single digit decrease. I'm not able to specifically say exactly which kind of low single digit, but that is a trend for sure that we expect in the future. Yes, of course, countries where there is a ban on smoke free can have some impact on this low single digit decline.

But nevertheless, that is a trend. That's what we have seen in Q2, largely in line with our expectation. And that's what we expect with for H2. With this impact of Turkey, that is a kind of transitional thing that is going to impact H2 more specifically. But otherwise, I think we are progressively going back to what we described as a normal long term trend for combustible.

Great. Thanks so much, Emmanuel. I'll pass it on.

Thank you. Our next question comes from Matt Smith with Stifel. Your line is open.

Hi. Emmanuel, I wanted to ask about the increase in the underlying guidance. The constant currency range is up about one point from the previous midpoint. That reflects the stronger second quarter and some favorability on the tax rate. Is it fair to say the second half is more or less in line with your previous expectations?

And can you provide a little more detail on the considerations in the second half? You called out phasing and comparisons and costs and the impact on margins from those and the timing of those when they become lapped into the base.

Yeah, I think when you look at there are of course a number of elements that can distort the vision quarter on quarter, H2 versus H1. What we wanted to ensure that everybody understands is that in fact the momentum in Q2 on Smokefree is in fact even better than Q1. And Q1 was already very good. But in fact, in Q2, we've seen an acceleration of IQOS in market sales. And we are nice to back to a nice double digit growth.

Very nice and very powerful reacceleration of ZYN in The U. S. Of course, elsewhere, ZYN and Vive are growing very fast. But Q2, in fact, is a very nice acceleration on our Smokefree business and this is absolutely visible in our numbers. When we look at H2, in fact, we expect the continuation of this very strong momentum that we've seen in H2 on Smokefree.

So we expect IQOS to continue to grow double digit in terms of adjusted IMS. We expect now that we have availability, which is no longer an issue for ZYN in The U. S, We expect the continuation of this very strong acceleration of ZYN in The U. S. Again, I reported 37% growth for the July.

So H2 is starting on a good note for ZYN in The U. S. So this momentum is unchanged and we expect it to remain very strong. Certainly, what is going to be less favorable is the trend on combustible. We were almost flat, minus 0.3% in volume in H1 and we expect 3% to 4% decline.

I've been explaining the driver for that. Despite that, we expect a growth on gross profit for combustible, but nevertheless at a lower level, of course than in H1. So this is one of the reasons for the differentiated performance in H2 versus H1 for what we can expect. And then you have a number of phasing element on Smokefree, which have nothing to do with performance, but which are due to basis of comparison or a number of one off events. If I look at IQOS, there was this $1,000,000,000 stick shipment in Q1 that we're going to compensate in Q4.

And of course, that is favoring H1 and penalizing H2. We had super favorable comps in H1 because of accelerated sales of devices last year that has been growing profit and margin. We're not going to have that in the second part of the year. So that's another element. And then you have the ZYN restocking that has been benefiting H1 and of course, will not be benefiting H2.

But I think that's really what is behind the guidance. And I think if you take all the elements I've just been sharing, you have the right understanding of the dynamic. I hope this is helpful.

Very helpful. And as a follow-up, pricing for heated tobacco units was up, I think, low single digits again in the quarter. You're about a year into realizing a nice contribution from pricing in that business. In the markets where you are taking pricing, how is that impacting volume in new user acquisition relative to your expectations and has that changed the way you think about the pricing potential in the HTU business over time? Thank you and I'll leave it there.

Yes, sure Matt. I think we're really trying to make sure we don't penalize volume with price increase when it comes to IQOS and ZYN because we describe how positive the volume growth is because we have higher revenue per unit, we have higher margin. So the name of the game is of course to absolutely optimize the volume. But there is obviously, as we are growing the franchise of the brand, the strength of the brand, there is a position to increase price without impacting the volume. And I think that is the right balance we're looking for, which is we increase volume, but we certainly don't want to change trajectory on volume because of that.

So price, yes, but provided it does not impact in a meaningful manner the volume trajectory. That is the strategy and that is what we will continue to do.

Thank you. Our next question comes from Bonnie Herzog with Goldman Sachs. Your line is open.

Thank you. Hi, Emmanuel. Good morning. Hi, Bonnie. Hi.

I had a few follow-up questions on ZYN. Based on everything you discussed and what you're seeing in the market, should we assume the lower end of your full year shipment guidance range is more realistic? I guess I'm trying to understand if the high end is even possible in your mind. And then can you update us on your capacity and where it stands today and when it will increase?

Sure. So of course, if we give this bracket, we believe that we can finish the year within the bracket at every point of the bracket, we give the EUR 800,000,000 to EUR $840,000,000. Clearly, the fact that this EUR 10,000,000 to EUR 20,000,000 lower restocking than what maybe we thought, I mean, that is having an impact. But at the end of the day, you can see that the restart of IQOS can be very powerful. I mean, 36%, 37%, we are restarting commercial activity, advertising.

So we don't know what's going to be the growth profile for H2. So that's why we are still comfortable with the 800,000,000 to $840,000,000 can bracket. On the capacity, we can say that today, have been building a comfortable capacity to face all kind of very dynamic growth scenario for the future. And therefore, are comfortable for the coming quarters.

Okay. Then maybe just another follow-up because you just touched on something that I also wanted to ask, which is now that you're, I guess, essentially back in the stock or you can ship to demand, how does that change your strategy it relates to your pricing, promotions? Are you going to, I guess, get a little bit more aggressive in an attempt to possibly grow ZYN faster and take more market share? Just how are you thinking about that? Thanks.

Yes, of course, Bonnie. So you're right. As I said, we go for putting all levers to maximize the growth of ZYN and all that in a very different environment because now we have full availability. So during many months, many quarters, we've been refraining ourselves from acquiring new users because we knew that we were not really able to supply the need for new users. So that means limited activity, I would say across the board.

So in terms of pricing, in terms of marketing activities. So we're going to restart normal activity and that will certainly include more promotion. We have a much lower level of promotion than any other brand and I think it will stay like that. But it doesn't mean that we cannot increase the level of promotion as well. That will be certainly advertising and commercial activity on the point of sales where we need to step up now that the product is available.

Philip Morris International (PM) Q2 2025 Earnings Call Transcript

Company Participants